

X-SPRAYS Appoints John Knapp as Chief Executive Officer

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Nov. 20, 2017 -- CNRP Mining Inc. (CSE:CND) (OTCQB:CRPGF) (the “**Company**” or “**CNRP Mining**”), is pleased to announce that X-SPRAYS, subject to regulatory approval, has appointed John Knapp as the new Chief Executive Officer effective immediately.

Mr. Knapp brings over 8 years of experience in the cannabis industry to X-SPRAYS. A pioneer in the legal cannabis industry, John Knapp is a co-founder of PharmaCielo, a Colombian based, internationally focused medicinal-grade cannabis extract company. Mr. Knapp is also the founder of Colorado-based Good Meds, an award-winning medical cannabis business with a 90,000 square foot cultivation and extraction facility that is vertically integrated via supplying to two dispensaries in the Denver market.

Mr. Knapp is experienced in the design and operation of cGMP grade cannabis cultivation and extraction facilities. His ‘smart design’ approach to the industry has been featured on the television news magazine “60 Minutes”. Under Mr. Knapp’s direction, the company evolved from a single-caregiver/wholesale operation to a thriving business with over 65 employees, designing and implementing seven commercial cultivation facilities in four years as well as a state of the art extraction processing and analysis laboratory.

Mr. Knapp holds a Bachelor of Science in Industrial Engineering from Western Michigan University.

“I look forward to working with the X-SPRAYS team and bringing my knowledge and experience in the international cannabis sector to help accelerate the go-to-market strategy and refine back end production, procurement and operations,” said Mr. Knapp.

About X-SPRAYS

X-SPRAYS is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts in creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS has developed a novel line of 8 health care and life enhancement nutraceutical products focused on enhancing pain relief, awareness, sleep, libido, energy and recovery.

The Company’s product line is ready for commercialization with 8 novel sprays that include both hemp cannabidiol (CBD) and nutraceutical ingredients (4 with CBD and 4 nutraceutical). X-SPRAYS intends to expand its product line to include cannabis Tetrahydrocannabinol (THC) and CBD sprays. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD

"Randy Clifford"
Director

For further information, please contact:

Randy Clifford
Telephone: 780-466-6006
Email: info@cnrprmining.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.